CD8A and neoplasm: An early burst of proliferating circulating CD8+ T cells is associated with clinical response to PD-1 pathway blockade; however, circulating activated CD8+ T cells eventually return to baseline levels following the presumed migration of these activated cells to tumor or other inflamed sites.22